Extracellular domain of HER2: A useful marker for the initial workup and follow-up of HER2-positive breast cancer

Journal of B.U.ON.

Volumn 13, Issue 3, 2008, Pages 409-413

  Garoufali, A ^a   Kyriakou, F ^a   Kountourakis, P ^a   Yioti, I ^a   Malliou, S ^a   Nikaki, A ^a   Kardara, E ^a   Frangos, I ^a   Koumna, S ^a   Baziotis, N ^a   Scorilas, A ^b   Ardavanis, Alexandros ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Breast cancer; HER2; HER2 extracellular domain; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADVANCED CANCER; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GRADING; CANCER LOCALIZATION; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; EARLY CANCER; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; RELIABILITY;

BREAST DISEASES; BREAST NEOPLASMS; CELL MEMBRANE; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 53849103976     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Stern DF, Hefferman PA, Weinberg RA. p185, a product of the neu proto-oncogene, is a receptor-like protein associated with tyrosine kinase activity. Mol Cell Biol 1986; 6: 1729-1740.
2. Yamamoto T, Ikawa S, Akiyama T et al. Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. Nature 1986; 319: 226-230.
3. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene. Science 1987; 235: 177-181.
4. Allred DC, Clark GM, Tandon AK et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992; 10: 599-605.
5. Stal O, Sullivan S, Wingren S et al. c-erbB2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 1995; 31A: 2185-2190.
6. De Placido S, De Laurentis M, Carlomagno C et al. Twenty-year results of the Naples GUN randomised trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 2003; 9: 1039-1046.
7. Yamauchi H, O Neil A, Gelman R et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/neu protein. J Clin Oncol 1997; 15: 2518-2525.
8. Lipton A, Ali SM, Leitzel K et al. Elevated serum HER-2/neu levels predict decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002; 20: 1467-1472.
9. Molina R, Jo J, Filella X et al. C-erbB-2, CEA, CA15.3 serum levels in the early diagnosis of recurrence of breast cancer patients. Anticancer Res 1999; 19: 2551-2555.
10. Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J, Baselga J. Cleavage of HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 1999; 59: 1196-1201.
11. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanised anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61: 4744-4749.
12. Muller V, Thomssen C, Karakas C et al. Quantitative assessment of HER-2/ neu protein concentration in breast cancer by enzyme-linked immunosorbent assay. Int J Biol Markers 2003; 18: 13-20.
13. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-2648.
14. Yamauchi H, Steams O, Hayds DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001; 19: 2334-2356.
15. Pegram MD, Lipton A, Hayes DF et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/ neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16: 2659-2671.
16. Souder C, Leitzel K, Ali SM et al. Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer. Cancer 2006; 107: 2337-2345.
17. Fornier NM, Seidman AD, Schwartz K et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 2005; 16: 234-239.
18. Esteva FJ, Valero V, Booser D et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 1800-1808.
19. Kostler WJ, Schwab B, Singer CF et al. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 2004; 10: 1618-1624.
20. Muller V, Witzel I, Luck HJ et al. Prognostic and predictive impact of the HER-2/neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer. Breast Cancer Res Treat 2004; 86: 9-18.
21. Ardavanis A, Kountourakis P, Kyriakou F et al. Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer. Oncologist 2008; 13: 361-369.
22. Bargmann CL, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor related protein. Nature 1986; 319: 226-230.
23. Schwartz MK, Smith C, Schwartz DC et al. Monitoring therapy by serum HER-2/neu. Int J Biol Markers 2000; 15: 324-329.